Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

532 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The promise of pharmacogenomics: gemcitabine and pemetrexed.
Rosell R, Taron M, Sanchez JM, Moran T, Reguart N, Besse B, Isla D, Massuti B, Alberola V, Sanchez JJ. Rosell R, et al. Among authors: sanchez jj, sanchez jm. Oncology (Williston Park). 2004 Nov;18(13 Suppl 8):70-6. Oncology (Williston Park). 2004. PMID: 15655942 Free article. Review.
Determinants of response and resistance to cytotoxics.
Rosell R, Monzó M, Alberola V, Taron M, Barnadas A, Sánchez JM, Manzano JL, Sanchez JJ. Rosell R, et al. Among authors: sanchez jj, sanchez jm. Semin Oncol. 2002 Feb;29(1 Suppl 4):110-8. doi: 10.1053/sonc.2002.31532. Semin Oncol. 2002. PMID: 11894021 Review.
Pemetrexed in previously treated non-small-cell lung cancer.
Rosell R, Sanchez JM, Taron M, Moran T, Ciuraqui B, Canela M, Felip E, Massuti B, Camps C. Rosell R, et al. Among authors: sanchez jm. Oncology (Williston Park). 2004 Jul;18(8 Suppl 5):63-71. Oncology (Williston Park). 2004. PMID: 15339062 Review.
14-3-3sigma methylation in pretreatment serum circulating DNA of cisplatin-plus-gemcitabine-treated advanced non-small-cell lung cancer patients predicts survival: The Spanish Lung Cancer Group.
Ramirez JL, Rosell R, Taron M, Sanchez-Ronco M, Alberola V, de Las Peñas R, Sanchez JM, Moran T, Camps C, Massuti B, Sanchez JJ, Salazar F, Catot S; Spanish Lung Cancer Group. Ramirez JL, et al. Among authors: sanchez jj, sanchez jm, sanchez ronco m. J Clin Oncol. 2005 Dec 20;23(36):9105-12. doi: 10.1200/JCO.2005.02.2905. J Clin Oncol. 2005. PMID: 16361617
Applications of genomics in NSCLC.
Rosell R, Cobo M, Isla D, Sanchez JM, Taron M, Altavilla G, Santarpia M, Moran T, Catot S, Etxaniz O. Rosell R, et al. Among authors: sanchez jm. Lung Cancer. 2005 Dec;50 Suppl 2:S33-40. Lung Cancer. 2005. PMID: 16557672 Review.
Novel approaches in the treatment of non-small-cell lung cancer.
Rosell R, Sánchez JM, Tarón M, O'Brate A, Gutiérrez JL, Monzó M, Felip E, Sánchez JJ, Alberola V. Rosell R, et al. Among authors: sanchez jj, sanchez jm. Oncology (Williston Park). 2001 Mar;15(3 Suppl 6):52-60. Oncology (Williston Park). 2001. PMID: 11301850 Free article. Review.
Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism.
Font A, Sánchez JM, Tarón M, Martinez-Balibrea E, Sánchez JJ, Manzano JL, Margelí M, Richardet M, Barnadas A, Abad A, Rosell R. Font A, et al. Among authors: sanchez jj, sanchez jm. Invest New Drugs. 2003 Nov;21(4):435-43. doi: 10.1023/a:1026251202137. Invest New Drugs. 2003. PMID: 14586211 Clinical Trial.
532 results